Adamas Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Adamas Pharmaceuticals, Inc.
The German group’s fibro-inflammatory deal with Kyowa Kirin has come in the same week as a new oncology collaboration with partner 3T and a liver disease alliance with China’s Ribo.
During Q4, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $1.9bn; while in vitro diagnostic firms and research tools players raised $848m.
The Swedish firm’s Parkinson's disease drug has failed to hit its primary endpoint in a Phase IIb study but Irlab believes that positive results on secondary goals merit further development of mesdopetam.
Building upon the May 2020 acquisition of US WorldMeds, Supernus is diversifying beyond Trokendi for epilepsy and will be able to rely on its existing commercial force for CNS products.
- Controlled Release
- Drug Delivery
- Other Names / Subsidiaries
- Osmotica Pharmaceutical US
- Supernus Pharmaceuticals, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.